药康生物8月28日获融资买入1158.30万元，融资余额1.11亿元

Core Insights - Jiangsu Jicui Pharmaceutical Technology Co., Ltd. (药康生物) reported a revenue of 375 million yuan for the first half of 2025, reflecting a year-on-year growth of 10.11% [2] - The company's net profit attributable to shareholders decreased by 7.12% year-on-year, amounting to approximately 70.91 million yuan [2] - As of June 30, 2025, the number of shareholders increased by 23.68% to 7,213, with an average of 56,841 circulating shares per shareholder, up 62.56% [2] Financing and Trading Activity - On August 28, 2023, the stock price of Jiangsu Jicui Pharmaceutical fell by 0.52%, with a trading volume of approximately 93.59 million yuan [1] - The financing buy-in for the company on the same day was 11.58 million yuan, while the financing repayment was 10.71 million yuan, resulting in a net financing buy-in of 868,200 yuan [1] - The total financing and securities lending balance reached 111 million yuan, representing 1.58% of the circulating market value, indicating a high level of financing activity [1] Shareholder and Institutional Holdings - Cumulative cash dividends distributed by Jiangsu Jicui Pharmaceutical since its A-share listing amount to 139 million yuan [3] - As of June 30, 2025, the top ten circulating shareholders included several institutional investors, with notable changes in holdings, such as a decrease of 1.24 million shares by China Europe Medical Health Mixed A [3] - New institutional investors included China Europe Sci-Tech Theme Mixed A, which entered the top ten shareholders with 5.64 million shares [3]